92 related articles for article (PubMed ID: 19878677)
1. Adding structural information to the von Hippel-Lindau (VHL) tumor suppressor interaction network.
Leonardi E; Murgia A; Tosatto SC
FEBS Lett; 2009 Nov; 583(22):3704-10. PubMed ID: 19878677
[TBL] [Abstract][Full Text] [Related]
2. Genotype-phenotype relations of the von Hippel-Lindau tumor suppressor inferred from a large-scale analysis of disease mutations and interactors.
Minervini G; Quaglia F; Tabaro F; Tosatto SCE
PLoS Comput Biol; 2019 Apr; 15(4):e1006478. PubMed ID: 30943211
[TBL] [Abstract][Full Text] [Related]
3. Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein.
Minervini G; Mazzotta GM; Masiero A; Sartori E; Corrà S; Potenza E; Costa R; Tosatto SC
Sci Rep; 2015 Jul; 5():12605. PubMed ID: 26211615
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product.
Tsuchiya H; Iseda T; Hino O
Cancer Res; 1996 Jul; 56(13):2881-5. PubMed ID: 8674032
[TBL] [Abstract][Full Text] [Related]
5. Insights into the molecular features of the von Hippel-Lindau-like protein.
Minervini G; Quaglia F; Tabaro F; Tosatto SCE
Amino Acids; 2019 Nov; 51(10-12):1461-1474. PubMed ID: 31485743
[TBL] [Abstract][Full Text] [Related]
6. Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis.
Forman JR; Worth CL; Bickerton GR; Eisen TG; Blundell TL
Proteins; 2009 Oct; 77(1):84-96. PubMed ID: 19408298
[TBL] [Abstract][Full Text] [Related]
7. Comparative sequence analysis of the VHL tumor suppressor gene.
Woodward ER; Buchberger A; Clifford SC; Hurst LD; Affara NA; Maher ER
Genomics; 2000 May; 65(3):253-65. PubMed ID: 10857749
[TBL] [Abstract][Full Text] [Related]
8. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
9. Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design.
Liu J; Nussinov R
Proc Natl Acad Sci U S A; 2008 Jan; 105(3):901-6. PubMed ID: 18195360
[TBL] [Abstract][Full Text] [Related]
10. Homology modeling and molecular dynamics simulation of the HIF2α degradation-related HIF2α-VHL complex.
Dong X; Su X; Yu J; Liu J; Shi X; Pan Q; Yang J; Chen J; Li L; Cao H
J Mol Graph Model; 2017 Jan; 71():116-123. PubMed ID: 27902963
[TBL] [Abstract][Full Text] [Related]
11. Computational and experimental characterization of dVHL establish a Drosophila model of VHL syndrome.
Shmueli MD; Schnaider L; Herzog G; Gazit E; Segal D
PLoS One; 2014; 9(10):e109864. PubMed ID: 25310726
[TBL] [Abstract][Full Text] [Related]
12. Experimental and computational studies indicate specific binding of pVHL protein to Aurora-A kinase.
Ferchichi I; Stambouli N; Marrackchi R; Arlot Y; Prigent C; Fadiel A; Odunsi K; Ben Ammar Elgaaied A; Hamza A
J Phys Chem B; 2010 Jan; 114(3):1486-97. PubMed ID: 20047310
[TBL] [Abstract][Full Text] [Related]
13. pVHL: a multipurpose adaptor protein.
Frew IJ; Krek W
Sci Signal; 2008 Jun; 1(24):pe30. PubMed ID: 18560019
[TBL] [Abstract][Full Text] [Related]
14. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity.
Li Z; Wang D; Na X; Schoen SR; Messing EM; Wu G
EMBO J; 2003 Apr; 22(8):1857-67. PubMed ID: 12682018
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
Tanimoto K; Makino Y; Pereira T; Poellinger L
EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113
[TBL] [Abstract][Full Text] [Related]
16. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion.
Datta K; Sundberg C; Karumanchi SA; Mukhopadhyay D
Cancer Res; 2001 Mar; 61(5):1768-75. PubMed ID: 11280720
[TBL] [Abstract][Full Text] [Related]
17. The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2.
Lolkema MP; Mans DA; Snijckers CM; van Noort M; van Beest M; Voest EE; Giles RH
FEBS Lett; 2007 Oct; 581(24):4571-6. PubMed ID: 17825299
[TBL] [Abstract][Full Text] [Related]
18. Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations.
Kishida T; Stackhouse TM; Chen F; Lerman MI; Zbar B
Cancer Res; 1995 Oct; 55(20):4544-8. PubMed ID: 7553625
[TBL] [Abstract][Full Text] [Related]
19. The von hippel-lindau tumor suppressor protein: an update.
Kaelin WG
Methods Enzymol; 2007; 435():371-83. PubMed ID: 17998064
[TBL] [Abstract][Full Text] [Related]
20. VHLdb: A database of von Hippel-Lindau protein interactors and mutations.
Tabaro F; Minervini G; Sundus F; Quaglia F; Leonardi E; Piovesan D; Tosatto SC
Sci Rep; 2016 Aug; 6():31128. PubMed ID: 27511743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
